No profile data available.
Iovance Biotherapeutics, Inc. (IOVA) is a healthcare company in the additional cancer treatment drugs industry, based in San Carlos, United States, with about 975 full-time employees.
It reported revenue of $263.50 million for fiscal year 2025, up 60.6% from fiscal year 2024, and net income of -$390.98 million. United States was its largest region in fiscal year 2025, with 98% of revenue. Its market capitalization was $6.62 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Iovance Biotherapeutics reported $263.50 million in revenue for fiscal year 2025, up 60.6% from $164.07 million in fiscal year 2024.
United States: 98% of revenue by region in fiscal year 2025, followed by Rest of World (2%).
$6.62 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Summit Therapeutics Inc. (SMMT), Halozyme Therapeutics, Inc. (HALO), ImmunityBio, Inc. (IBRX), CG Oncology, Inc. (CGON).